Hormone replacement therapy and risk of breast cancer with a favorable histology: Results of the Iowa Women's Health Study

JAMA

Volumn 281, Issue 22, 1999, Pages

  Gapstur, Susan M ^a   Morrow, Monica ^a   Sellers, Thomas A ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; DOSE RESPONSE; FEMALE; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 0344517349     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.22.2091     Document Type: Article

References (34)

1. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med. 1994;330:1062-1071.
2. The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density. JAMA. 1996; 276:1389-1396.
3. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progesterone use and risk of cardiovascular disease. N Engl J Med. 1996;335: 453-461.
4. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117: 1016-1037.
5. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer. H Natl Cancer Inst. 1998;90:1371-1388.
6. Jordan VC, Glusman JE, Eckert S, et al. Incident primary breast cancers are reduced by raloxifene. Proc Am Soc Clin Oncol. 1998;17:466.
7. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy. Lancet 1997;350:1047-1059.
8. Shairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control. 1994; 5:491-500.
9. Longnecker MP, Bernstein L, Paganini-Hill A, Enger SM, Ross RK. Risk factors of in situ breast cancer. Cancer Epidemiol Biomarkers Prev. 1996;5:961-965.
10. Stanford JL, Wiess NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA. 1995; 274:137-142.
11. Rosen PP. The pathological classification of human mammary carcinomas: past, present and future. Ann Clin Lab Sci. 1979;9:144-156.
12. Claus EB, Risch N, Thompson WD, Carter D. Relationship between breast histopathology and family history of breast cancer. Cancer 1993;71:147-153.
13. Perez-Mesa CM. Gross and microscopic pathology. In: Donegan WL, Spratt JS, eds. Cancer of the Breast. 3rd ed. Philadelphia, Pa: WB Saunders Co; 1988:206-249.
14. Sellers TA, Kushi LH, Potter JD, et al. Effect of family history, body-fat distribution, and reproductive factors on the risk of postmenopausal breast cancer. N Engl J Med. 1992;326:1323-1329.
15. Bisgard KM, Folsom AR, Hong CP, Sellers T. Mortality and cancer rates in nonrespondents to a prospective study of older women: 5-year follow-up. Am J Epidemiol. 1994;139:990-1000.
16. Kushi LH, Kaye SA, Folsom AR, Soler JT, Prineas RJ. Accuracy and reliability of self-measurements of body girths. Am J Epidemiol. 1988;128:740-748.
17. Willett WC, Sampson L, Browne ML, et al. The use of a self-administered questionnaire to assess diet four years in the past. Am J Epidemiol. 1988;127: 188-199.
18. Gapstur SM, Potter JD, Folsom AR. Increased risk of breast cancer with alcohol consumption in post-menopausal women. Am J Epidemiol. 1993;136: 1221-1231.
19. Munger RG, Folsom AR, Kushi LH, et al. Dietary assessment of older Iowa women with a food frequency questionnaire. Am J Epidemiol. 1992;136: 192-200.
20. Dubin N, Pasternack BS. Risk assessment for case-control subgroups by polychotomous logistic regression. Am J Epidemiol. 1986;123:1101-1117.
21. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336:1769-1775.
22. Willis DB, Calle EE, Miracle-McMahill HL, Heath CW. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control. 1996;7:449-457.
23. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991;151:75-78.
24. Bergkvist L, Adami HO, Persson I, Bergström R, Krusemo UB. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol. 1989;130:221-228.
25. Strickland DM, Gambrell D, Butzin CA, Strickland K. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol. 1992;80:400-404.
26. Ewertz M, Gillanders S, Meyer L, Zedelz K. Survival of breast cancer patients in relation to factors which affect the risk of developing breast cancer. Int J Cancer. 1991;49:526-530.
27. Holli K, Isola J, Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol. 1998;16:3115-3120.
28. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Peana L. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol. 1995;85:11-17.
29. Squitieri R, Tartter PI, Ahmed S, Browser ST, Theise ND. Carcinoma of the breast in postmenopausal hormone user and nonuser control groups. J Am Coll Surg. 1994;178:167-170.
30. Weiss NS. Noncontraceptive estrogens and abnormalities of endometrial proliferation. Ann Intern Med. 1978;88:410-412.
31. Hemminki E, Kennedy DL, Baum C, McKinlay SM. Prescribing of noncontraceptive estrogens and progestins in the United States 1974-86. Am J Public Health. 1988;78:1479-1481.
32. Nabulsi AA, Folsom AR, White A, et al. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 1993;328:1069-1075.
33. Wysowsky DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol. 1995;85:6-10.
34. Ries LAG, Kosary CL, Hankey BF, Miller BA, Edwards BK, eds. SEER Cancer Statistics Review, 1973-1995. Bethesda, Md: National Cancer Institute; 1998.